Notícias e Atividades da Immuneering

Immuneering é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Immuneering é uma empresa listada sob o símbolo IMRX (US).

Veja o organograma con seus 32 executivos principais

Biografias mais buscadas da Immuneering

• Ben Zeskind, President, Chief Executive Officer and Director
• Bob Carpenter, Chair Emeritus
• Laurie Keating, Director

Recentes movimentos de executivos em Immuneering

• Andrew Gengos ingressará na Companhia como Chief Financial Officer em 16 de jul. de 2026  (Notícia publicada em 16 de junho de 2026).

Criar um alerta
para seguir os movimentos de executivos da Immuneering.

Immuneering possui 2.428 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).

Popular M&A news in Biotecnologia

• Eli Lilly has announced the acquisition of AtaiBeckley  (publicado em 17 de julho de 2026).
• GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
• Clearside Biomedical has gone out of its bankruptcy protection  (publicado em 15 de julho de 2026).

Outros contatos sugeridos na indústria do Biotecnologia

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer da Inceptive
• Jan Van de Winkel - President and Chief Executive Officer da Genmab
• Robert Gould - Board Member da Fulcrum Therapeutics

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Immuneering

• 1-year survival nearly doubles in trial of pancreatic cancer therapy
• Immuneering progresses MAPK inhibitor in lung and pancreatic cancer
• Pancreatic cancer treatment atebimetinib set for Phase 3 trial
• Immuneering’s pancreatic cancer pill continues to beat standard care, updated first-line data show
• Immuneering builds momentum with additional first-line pancreatic cancer data, aims for Phase 3 this year
• The MEK effect on cancer — a slow and steady approach to drug resistance
• Immuneering says MEK pill beats standard of care in first-line pancreatic cancer
• Immuneering Announces Participation in William Blair Biotech Focus Conference 2022 | Immuneering Corporation
• Immuneering Reports Data in Two Preclinical Abstracts at the ASCO 2022 Annual Meeting Highlighting Pan-KRAS/NRAS Activity of IMM-1-104 | Immuneering Corporation
• Press Releases | Immuneering Corporation
• View more press releases Close

Redes sociais sobre Immuneering

• Immuneering na Wikipedia, Google News e Yahoo Finance
• Immuneering na LinkedIn, X (Twitter) e YouTube